Aspect Biosystems IDTechEx analyst Nadia Tsao interviewed Aspect Biosystems' Tamer Mohamed and Thomas Lum on 16 June, 2017. Aspect Biosystems is a Canadian 3D bioprinting company developing a proprietary lab-on-a-printer technology. History Aspect Biosystems is a Canadian biotechnology company spun out of two research groups in engineering and medicine at the University of British Columbia in Vancouver. The company was founded in November 2013 by Tamer Mohamed, Dr Konrad Walus, Dr Sam Wadsworth, and Simon Beyer.
The goals of the company are to work towards a future where drug efficacy can be determined for patients before prescription, animals are no longer needed for drug testing, and lifesaving transplant organs are created and not harvested. To start, the company aims to create physiologically-relevant 3D human tissue models for drug discovery and development. They hope that the pharmaceutical industry can use their technology to retest therapeutics that have been shelved due to lack of appropriate models. For the long term, their vision is to provide personalized and regenerative medicine.
In January 2017, Aspect Biosystems announced a research collaboration with DePuy Synthes (a Johnson & Johnson company) to develop 3D bioprinted knee meniscus for surgical therapy. Aspect Biosystems